Cabrera JP, Caselli BE, Elgueta ML, Frelinghuysen MD, Molina HE

Language: Spanish
References: 10
Page: 53-58
PDF size: 71.49 Kb.

ABSTRACT

Introduction: The esophagic cancer is caracterized by late diagnosis, poor survival rate and low quality of life for this patients. Reject or non treatment is a situation that not always is important to physicians. Objective: Caracterize all the patients diagnosed with esophagic cancer that reject or relieve no treatment in this center. Material and Method: We did a descriptive transversal study in 17 patients with diagnosis of esophagic cancer between the years 2002 and 2006, that rejected or not treatment. We studied by sex, age, location, deep of penetration, histology of the tumour. Analysis of survival by Kaplan-Meier method. Results: Men 14(82%) and women 3(18%). Age average 67 years, between 45-90. The location of the tumour was 5(29%) upper third and 4(24%) distal third. 16 patients (94%) at the moment of the diagnosis was advanced cancer. One patient (6%) did not any study of the tumour. Histology. Squamous 15(88%), adenomarcinoma 1(6%) and melanoma 1(6%). Survival. 14 patients (82%) were less than or equal to 4 months, and 3 patients (18%) greater to this. Average of survival was 2 months, the survival to 8 months was 0%. Conclusion: The reject or non treatment to show especially in males and is asociated with a poor survival, because any patient will get better the 8 months at the moment of the diagnosis. It is necessary to make an effort for change this situation. [Reject or non treatment of patients diagnosed with esophagic cancer.]

REFERENCES

1. Braghetto I, Csendes A, Cornejo A, Amat J, Cardemil G et al. Sobrevida de pacientes con cáncer de esófago sometidos a esofagectomía total torácica. Rev. Méd. Chile 2000; 1: 64-74.

2. Alvarez R, Seguel E, Betancur C. Carcinoma escamoso de esófago con metástasis al estómago. Rev. Chil. Cir. 2002; 3: 284-287.

3. Alvarez R, Seguel E, Betancur C, Zúñiga C, Gallardo A et al. Recidiva tumoral en tubo gástrico en esofagectomías por carcinoma. Rev. Chil. Cir. 2002; 1: 49-52.

4. Alvarez R, Klaassen R, Molina H, Torres O, Cancino A et al. Carcinoma superficial de esófago: análisis clínico-patológico y sobrevida. Rev. Chil. Cir. 2003; 2: 160- 164.

5. Venturelli A, Soto S, Díaz J, Cardemil B, Sánchez A et al. Cáncer de esófago, tratamiento en el Hospital Clínico Regional de Valdivia durante el período 1982- 2001. Rev. Chil. Cir. 2003; 4: 381-384.

6. Wang G, Jiao G, Chiang F, Fang W, Song J et al. Long-term results of operation for 420 patients with early squamous cell esophageal carcinoma discovered by screening. Ann.Thorac.Surg 2004; 77: 1740-4

7. Blom D, Peters J, DeMeester T. Controversies in the current therapy of the carcinoma of esophagus. J. Am. Coll. Surg 2002; 195: 241-50.

8. Lehnert T. Multimodal therapy for squamous carcinoma of esophagus. Br. J. Surg. 1999; 86: 727-39.

9. Venturelli A, Sánchez A, Cardemil B. Cáncer de esófago. Sobrevida a diez años plazo. Rev. Chil. Cir. 2001; 53: 241-5.

10. Bonavina L, Ruol A, Ancona E, Peracchia A. Prognosis of early squamous cell carcinoma of the esophagus after surgical therapy. Dis. esophagus 1997; 10: 162- 4.